Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Liquidia Corp (LQDA)

Liquidia Corp (LQDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,424,180
  • Shares Outstanding, K 85,485
  • Annual Sales, $ 14,000 K
  • Annual Income, $ -130,390 K
  • EBIT $ -128 M
  • EBITDA $ -126 M
  • 60-Month Beta 0.24
  • Price/Sales 103.96
  • Price/Cash Flow N/A
  • Price/Book 29.25

Options Overview Details

View History
  • Implied Volatility 119.64% ( -1.36%)
  • Historical Volatility 76.64%
  • IV Percentile 98%
  • IV Rank 92.25%
  • IV High 126.51% on 08/16/24
  • IV Low 37.96% on 01/23/25
  • Put/Call Vol Ratio 0.15
  • Today's Volume 881
  • Volume Avg (30-Day) 3,336
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 71,494
  • Open Int (30-Day) 59,923

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.43
  • Number of Estimates 6
  • High Estimate -0.35
  • Low Estimate -0.50
  • Prior Year -0.37
  • Growth Rate Est. (year over year) -16.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.85 +24.70%
on 04/29/25
19.41 -17.41%
on 05/16/25
+2.54 (+18.83%)
since 04/22/25
3-Month
11.26 +42.36%
on 04/09/25
19.41 -17.41%
on 05/16/25
-0.08 (-0.53%)
since 02/21/25
52-Week
8.26 +94.07%
on 08/19/24
19.41 -17.41%
on 05/16/25
+2.90 (+22.09%)
since 05/22/24

Most Recent Stories

More News
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

LQDA : 15.93 (-4.38%)
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

LQDA : 15.93 (-4.38%)
Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference

LQDA : 15.93 (-4.38%)
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

LQDA : 15.93 (-4.38%)
Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

LQDA : 15.93 (-4.38%)
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

LQDA : 15.93 (-4.38%)
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

LQDA : 15.93 (-4.38%)
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIAâ„¢ (treprostinil) Inhalation Powder

LQDA : 15.93 (-4.38%)
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference

LQDA : 15.93 (-4.38%)
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update

LQDA : 15.93 (-4.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of...

See More

Key Turning Points

3rd Resistance Point 17.97
2nd Resistance Point 17.63
1st Resistance Point 17.14
Last Price 15.93
1st Support Level 16.31
2nd Support Level 15.97
3rd Support Level 15.48

See More

52-Week High 19.41
Last Price 15.93
Fibonacci 61.8% 15.15
Fibonacci 50% 13.84
Fibonacci 38.2% 12.52
52-Week Low 8.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar